Dual Antiplatelet Therapy After Vertebral Artery Stenting
For vertebral artery stenting, administer aspirin 81-100 mg daily plus clopidogrel 75 mg daily for a minimum of 30 days, with continuation for at least 3 months being reasonable, followed by lifelong single antiplatelet therapy.
Specific DAPT Regimen
The 2011 ASA/ACCF/AHA guideline on extracranial carotid and vertebral artery disease provides the framework for antiplatelet management after vertebral artery revascularization 1:
- Aspirin: 75-325 mg daily (Class I, Level B)
- P2Y12 inhibitor: Clopidogrel 75 mg daily is the agent of choice
- Loading dose: Clopidogrel 600 mg loading (or >5 days of maintenance therapy before procedure)
Duration Strategy
While vertebral artery stenting-specific duration data are limited, the guideline recommends extrapolating from carotid artery stenting (CAS) protocols 2:
Minimum 30 days of DAPT is mandatory (Class I, Level C) 2. This represents the absolute minimum to prevent catastrophic stent thrombosis during the highest-risk period.
3-6 months is more appropriate for most patients, based on:
- Carotid stenting guidelines recommending DAPT "for a minimum of 30 days" but with surveillance intervals at 1 month, 6 months, and annually 2
- Recent high-quality data showing 3-month DAPT after CAS provides equivalent efficacy to longer durations with reduced bleeding 3
- Intracranial stenting literature (anatomically adjacent) supporting 3-month DAPT duration 4
Post-DAPT Maintenance
After completing DAPT, continue single antiplatelet therapy indefinitely 1:
- Aspirin 75-325 mg daily (preferred), OR
- Clopidogrel 75 mg daily (if aspirin intolerant)
This lifelong single antiplatelet therapy is Class I, Level B recommendation for all patients with vertebral atherosclerosis 1.
Critical Caveats
Avoid prasugrel and ticagrelor in this setting. These agents are contraindicated or not recommended for cerebrovascular stenting due to:
- Prasugrel: Contraindicated with prior stroke/TIA history (Class III) 5
- Ticagrelor: Not studied in vertebral/carotid stenting; European guidelines explicitly state "not recommended" for triple therapy scenarios involving cerebrovascular disease 6
Clopidogrel is the only P2Y12 inhibitor with established safety in cerebrovascular stenting 2, 5.
Bleeding Risk Mitigation
- Use low-dose aspirin (81-100 mg) rather than higher doses 5
- Consider proton pump inhibitors for patients with GI bleeding history or increased risk 5
- Reassess bleeding risk at each follow-up; if life-threatening bleeding occurs, discontinuation after 1 month may be reasonable (Class IIb) 5
Surveillance Protocol
Serial noninvasive imaging (CTA or MRA) is reasonable at 1, 2:
- 1 month
- 6 months
- Annually thereafter
This mirrors carotid revascularization surveillance and allows for early detection of restenosis or new lesions.
Special Consideration: Anticoagulation
If oral anticoagulation becomes necessary (e.g., atrial fibrillation develops), minimize triple therapy duration. Consider early aspirin cessation (≤1 week) and continuation of oral anticoagulant plus clopidogrel only 7, 5, 6. Target INR 2.0-2.5 if using warfarin 5.